



IFW  
Certificate of Mailing (37 C.F.R. §1.8);  
I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
First Class Mail in an envelope addressed to:  
Commissioner for Patents, PO Box 1450, Alexandria,  
VA 22313-1450, on this 30th day of July 2004.

s/ Pamela Hollander  
Pamela Hollander

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:  
Allen BORCHARDT, et al.

Serial No.: 10/718,337

Confirmation No.: 9247

Filed: November 19, 2003

For: INHIBITORS OF HEPATITIS C VIRUS  
RNA-DEPENDENT RNA POLYMERASE,  
AND COMPOSITIONS AND TREATMENTS  
USING THE SAME

Group Art Unit: 1625

Examiner: Not Yet Assigned

Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

- |   |                  |
|---|------------------|
| 1. Return Receipt Postcard                  | 1 postcard;      |
| 2. Transmittal of IDS                       | 1 page;          |
| 3. Co-Pending US Application No. 10/299,510 | 282 total pages; |
| 4. PTO.SB/08A Form 1449                     | 8 pages; and     |
| 5. Copies of cited References               | 74 References    |

Respectfully submitted,

Date: July 30, 2004

Jeff Tidwell  
Jeffrey M. Tidwell  
Attorney For Applicants  
Registration No. 47,995

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 638-3877  
Fax: (858) 678-8233



Certificate of Mailing (37 C.F.R. §1.8):

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on this 30th day of July 2004.

s/ *Pamela Hollander*  
Pamela Hollander

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
**Allen BORCHARDT, et al.**

Serial No.: **10/718,337**

Confirmation No.: **9247**

Filed: **November 19, 2003**

For: **INHIBITORS OF HEPATITIS C VIRUS  
RNA-DEPENDENT RNA POLYMERASE,  
AND COMPOSITIONS AND TREATMENTS  
USING THE SAME**

Group Art Unit: **1625**

Examiner: **Not Yet Assigned**

Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.97(b) or 1.97(c)**

**37 CFR § 1.97(b)**

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

**37 CFR § 1.97(c)**

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.



Applicant requests that the Examiner consider the following copending applications:

Application Serial No.	Filing Date
10/271,467 (see US 2003 / 0171425 A1)	
10/299,510	

☒ Copies of these copending applications are enclosed.

☒ Applicant hereby requests consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith. Copies of the cited references, except as noted below, are enclosed.

☐ This application is a continuation, divisional or continuation-in-part of Serial No. . Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.


☒ This application was filed after June 30, 2003, or entered U.S. national stage under 35 U.S.C. § 371, after June 30, 2003. Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (1276 OG 55).

☐ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: July 30, 2004

  
Jeffrey M. Tidwell  
Attorney For Applicants  
Registration No. 47,995


Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 638-3877  
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/718,337
Filing Date	November 19, 2003
First Named Inventor	Allen BORCHARDT
Art Unit	1625
Examiner Name	To Be Assigned
Attorney Docket Number	PC25603A

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No.	DOCUMENT NUMBER Number-Kind Code <sup>2</sup>	Publication Date	Name of Patentee or Applicant of Cited	Pp., Columns, Lines, Where Relevant
	AA	US 3,786,063 A	01-15-1974	ARNOLD, R.J.	
	AB	US 4,326,058	04-20-1982	OKABE, T., et al.	
	AC	US 4,489,077	12-18-1984	SIRCAR, J., et al.	
	AD	US 4,591,583	05-27-1986	HELGSTRAND, et al.	
	AE	US 5,504,104	04-02-1996	ELLSWORTH, E.L., et al.	
	AF	US 5,789,440	08-04-1998	ELLSWORTH, E.L., et al.	
	AG	US 5,808,062	09-15-1998	DOMAGALA, J.M., et al.	
	AH	US 5,834,506	11-10-1998	BOYER, Jr., et al.	
	AI	US 5,840,751	11-24-1998	ELLSWORTH, E.L., et al.	
	AJ	US 5,846,964	12-08-1998	OZEKI, T.	
	AK	US 5,936,128	08-10-1999	ELLSWORTH, E.L., et al.	
	AL	US 6,046,355	04-04-2000	BOYER, Jr., et al.	
	AM	US 6,174,868	01-16-2001	ANDERSON, et al.	
	AN	US 6,512,006	01-28-2003	BOYER, Jr., et al.	
	AO	US 6,528,510	03-04-2003	BOYER, Jr., et al.	
	AP	US 2003 / 0171425 A1	09-11-2003	BOYER, Jr., et al.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/718,337
Filing Date	November 19, 2003
First Named Inventor	Allen BORCHARDT
Art Unit	1625
Examiner Name	To Be Assigned
Attorney Docket Number	PC25603A

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. 1	Foreign Patent Document	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pp., Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	AQ /	WO 95 14012 A	05-26-1995	ELLSWORTH, E.L., et al.		
	AR /	WO 95 14011 A	05-26-1995	ELLSWORTH, E.L., et al.		
	AS /	WO 98 19997	05-14-1998	BOYER, Jr., et al.		
	AT /	WO 015634	03-23-2000	BOYER, Jr., et al.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pp.(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AU	ALLEN, C.F.H., et al. "The Structure of Certain Polyazaindenes. III. 1,2,3a,7- and 1,3,3a,7-Tetrazaindenes," <i>J. Org. Chem.</i> , 1959, pp. 793 - 796, vol. 24.	
	AV	BAGINSKI S., et al. "Mechanism of Action Of A Pestivirus Antiviral Compound," <i>Proc. Natl. Acad. Sci. USA</i> , 2000, pp. 7981-7986, vol. 97.	
	AW	BAGSHAW, K., "Antibody-Directed Enzyme Prodrug Therapy: A Review," <i>Drug. Development Research</i> , 1995, pp. 220-230, vol. 34.	
	AX	BARTENSCHLAGER, R., et al., "Molecular Targets In Inhibition Of Hepatitis C Virus Replication" <i>Antiviral Chemistry &amp; Chemotherapy</i> , 1997, pp. 281-301, vol. 8, no. 4.	
	AY	BARTENSCHLAGER, R., et al., "Nonstructural Protein 3 Of The Hepatitis C Virus Encodes A Serine-Type Proteinase Required For Cleavage At The NS3/4 And NS4/5 Junctions," <i>Journal of Virology</i> , July 1993, pp. 3835-3844, vol. 67, no. 7.	
	AZ	BERGMAN, J., et al, "Synthesis of Chrysogine, a Metabolite of <i>Penicillium chrysogenum</i> and some related 1-substituted 4-(3H)-Quinazolinones," <i>Tetrahedron</i> , 1990, pp. 1295-1310, vol. 46.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/718,337
Filing Date	November 19, 2003
First Named Inventor	Allen BORCHARDT
Art Unit	1625
Examiner Name	To Be Assigned
Attorney Docket Number	PC25603A

BA	BERTOLINI, et al., "A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug," <i>J. Med. Chem.</i> , 1997, pp. 2011-2016, vol. 40, issue 13.
BB	BODOR, N, "Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems," <i>Advances in Drug Research</i> , 1984, pp. 255-331, vol. 13.
BC	BOYER, F.E., et al., 5,6-Dihydropyran-2-ones Possessing Various Sulfonyl Functionalities: Potent Nonpeptidic Inhibitors of HIV Protease", <i>J. Med. Chem.</i> , 2000, pages 843-858, vol. 43, no.
BD	BROWN, E.A., et al., "Secondary Structure Of The 5' Nontranslated Regions of Hepatitis C Virus And Pestivirus Genomic RNAs," <i>Nucleic Acids Research</i> 1992, pp. 5041-5045, vol. 20, no. 19.
BE	BUKH, J., et. al., "Sequence Analysis of the 5' Noncoding Region of Hepatitis C Virus," <i>Proc. National Academy of Science USA</i> , 1992, pp. 4942-4946, vol. 89.
BF	BUNDGAARD, H., et al., <i>Design and Application of Prodrugs, Drug Design and Development</i> , 1991, Krogsgaard-Larsen, et al., editors, Harwood Academic Publishers.
BG	BURKE, T.R., et al., "Conformationally Constrained Phosphotyrosyl Mimetics Designed As Monomeric Src Homology 2 Domain Inhibitors," <i>J. Med. Chem.</i> 1995, pp. 1386-1396, vol. 38.
BH	CARVALHO, C.F., et al., "Naturally Occurring Dibenzofurans. Part 6. Synthesis Of Didymic Acid," <i>J. Chem Soc. Perkin Trans 1</i> , 1984, pp. 1621-1626.
BI	CHAVIGNON, O., et al., "Pyrrolozation Processes Of Vinyl Substitued Imidazo[1,2- $\alpha$ ]pyridine, Pyrimidine And 1,8-Naphthyridine," <i>J. Heterocyclic Chem.</i> , 1992, pp. 691-697, vol. 29.
BJ	CHOO, Q.-L., et al., "Isolation of a cDNA Clone Derived From A Blood-Borne Non-A, Non-B Viral Hepatitis Genome," <i>Science</i> , April 21, 1989, pp. 359-362, vol. 244.
BK	CUTHBERT, J., "Hepatitis C: Progress and Problems" <i>Clinical Microbiology Reviews</i> , October 1994, pages 505-532, vol. 7, no. 4.
BL	DEAR, G.J., et. al., "Mass Directed Peak Selection, an Efficient Method of Drug Metabolite Identification Using Directly Coupled Liquid Chromatography-Mass Spectrometry-Nuclear Magnetic Resonance Spectroscopy," <i>Journal of Chromatography B</i> , 2000, pp. 281-293, vol. 748.
BM	DORIA, G., et al, "7-Trans-(2-Pyridylethenyl)-5H-Thiazolo[3,2-a] Pyrimidine-5-Ones: Synthesis And Pharmacological Activity," <i>Farmaco Ed. Sci.</i> , 1985, pp. 885-895

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/718,337
Filing Date	November 19, 2003
First Named Inventor	Allen BORCHARDT
Art Unit	1625
Examiner Name	To Be Assigned
Attorney Docket Number	PC25603A

BN	DOYLE, M., et al., "Macrocyclic Formation By Catalytic Intramolecular Cyclopropanation. A New General Methodology For The Synthesis Of Macrolides" <i>Journal of the American Chemical Society</i> , 1997, pages 8826-8837.
BO	EARL, R A., et al., The preparation of 2(1H)-pyridinones and 2,3-dihydro-5(1H)-indolizinones via transition metal mediated cocyclization of alkynes and isocyanates. A novel construction of the antitumor agent camptothecin, <i>Journal of Organic Chemistry</i> , 1984, pp. 4786-4800, vol. 149
BP	ELLSWORTH, E.L., et al., "4 Hydroxy -5,6-Dihydro-2H-Pyran-2-ones. 3.Bicyclic and Hetero-Aromatic Ring Systems as 3-Position Scaffolds to Bind to S <sub>1</sub> 'nd S <sub>2</sub> ' of the HIV-1 Protease Enzyme," <i>Bioorg. Med. Chem. Lett.</i> , 1999, pp. 2019-2024, vol. 9, issue 14.
BQ	FERRARI, E., et. al., "Characterization of Soluble Hepatitis C Virus RNA-Dependent RNA Polymerase Expressed in Escherichia Coli," <i>Journal of Virology</i> , 1999, pp. 1649-1654, vol. 73, no. 2.
BR	FRANCKI, et al., "Some observations on the Binding Properties of Alfalfa Mosaic Virus to Polystyrene and its significance to indirect ELISA," <i>Arch. Virol.</i> , 1991, pp. 219-235, vol. 2.
BS	GERECKE, M., et al, "New Tetracyclic Derivatives of Imidazo-[1,5-a][1,4]Benzodiazepines and of Imidazo [1,5-a]Thieno[3,2-f][1,4]Diazepines," <i>Heterocycles</i> , 1994, pp. 693-721, vol. 39, no. 2.
BT	GRAKOU, A., et al., "Expression And Identification Of Hepatitis C Virus Polyprotein Cleavage Products" <i>Journal Of Virology</i> , March 1993, pp. 1385-1395, vol. 67, no. 3.
BU	HAGEN, et al., "4-Hydroxy-5,6-dihydropyrones as Inhibitors of HIV Protease: The Effect of Heterocyclic Substituents at C-6 on Antiviral Potency and Pharmacokinetic Parameters" <i>J. Med</i>
BV	HAGEN, S., et al., "Synthesis of 5,6-Dihydro-4-hydroxy-2-pyrones as HIV-1 Protease Inhibitors: The Profound Effect of Polarity on Antiviral Activity," <i>J. Med Chem.</i> , 1997, pp. 3707-3711, vol. 40, issue 23.
BW	HÉNICHART, J., et al., "A Convenient Method For The Preparation Of ω-Di-Alkylaminoalkyl Isothiocyanates," <i>Synthesis</i> , 1980, pp. 311-312.
BX	HIJIKATA, M., et al., "Gene Mapping Of The Putative Structural Region Of The Hepatitis C Virus Genome By In Vitro Processing Analysis" <i>Proc. Natl. Acad. Sci. USA</i> , July 1991, pp. 5547-5551, vol. 88.
BY	HWANG, S.B., et al., "Hepatitis C Virus NS5B Protein Is A Membrane-Associated Phosphoprotein With A Predominantly Perinuclear Localization," <i>Virology</i> , 1997, pp. 439-446, vol. 227.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

## **Complete if Known**

Application Number	10/718,337
Filing Date	November 19, 2003
First Named Inventor	Allen BORCHARDT
Art Unit	1625
Examiner Name	To Be Assigned
Attorney Docket Number	PC25603A

BZ	ISHII, et al., "Expression of Hepatitis C Virus NS5B Protein: Characterization of Its RNA Polymerase Activity and RNA Binding", <i>Hepatology</i> , 1999, pages 1227-1235, Vol. 29.
CA	ISHIZUMI, K., et al. "Synthesis And Anxiolytic Activity of N-Substituted Cyclic Imides (1R*, 2S*, 3R*, 4S*)-N-[4-(2-Pyrimidinyl)-1-Piperazinyl]butyl]-2,3-Bicyclo[2.2.1]Heptanedicarboximide (Tandospirone) And Related Compounds," <i>Chem. Pharm Bull.</i> , 1991, pp. 2288-2300, vol. 39, no. 9.
CB	KIM, et al., "Hepatitis C Virus NS3 RNA Helicase Domain With A Bound Oligonucleotide: The Crystal Structure Provides Insights Into The Mode Of Unwinding" <i>Structure</i> , 1998, pages 89-100, vol. 6, no. 1.
CC	KIM, et al., "Crystal Structure Of The Hepatitis C Virus NS3 Protease Domain Complexed With A Synthetic NS4A Cofactor Peptide," <i>Cell</i> , October 18, 1996, pp. 343-355, vol. 87.
CD	KOLYKHALOV, A.A., et. al., "Identification of a Highly Conserved Sequence Element at the 3' Terminus of Hepatitis C Virus Genome RNA," <i>Journal of Virology</i> , 1996, pp. 3363-3371, vol. 70, no. 9.
CE	KUCHAR, M., et al., "The Synthesis Of Arylpropionic Acids And The Quantitative Relationship Between The Structure And The Activation Of Fibrinolysis," <i>Collect. Czech. Chem. Commun</i> , 1981, pp. 1173-1187, vol. 46.
CF	LEE, Y.R., et al., "A New Route For The Synthesis of Furanoflavone And Furanochalcone Natural Products," <i>Tetrahedron</i> , 1995, pp. 4909-4922, vol. 51.
CG	LIN, C., et al., "Processing In The Hepatitis C Virus E2-NS2 Region: Identification of p7 and Two Distinct E2-Specific Products With Different C Termini," <i>Journal of Virology</i> , August 1994, pp. 5063-5073, vol. 68, no. 8.
CH	LOHMANN, V., et al., Biochemical Properties of Hepatitis C Virus NS5B RNA-Dependant RNA Polymerase and Identification of Amino Acid Sequence Motifs Essential for Enzymatic Activity, <i>J. Virol.</i> , 1997, pp. 8416-8428, vol. 71.
CI	LOHMANN, V., et al., "Biochemical And Kinetic Analyses Of NS5B RNA-Dependent RNA Polymerase Of The Hepatitis C Virus" <i>Virology</i> , 1998, pp. 108-118.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*\*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/718,337
Filing Date	November 19, 2003
First Named Inventor	Allen BORCHARDT
Art Unit	1625
Examiner Name	To Be Assigned
Attorney Docket Number	PC25603A

CJ	LORENTZEN, R. et al., "Application Of The Benzene Sector And The Benzene Chirality Rules To Perhydrobenzocycloalkenes And Related Compounds," <i>Journal Amer. Chem. Soc.</i> , 1992, pp. 2181-2187, vol. 114.
CK	LOVE, et al., "The Crystal Structure Of Hepatitis C Virus NS3 Proteinase Reveals A Trypsin-Like Fold And A Structural Zinc Binding Site" <i>Cell</i> , 1996, pp. 331-342, vol. 87.
CL	MARCELLIN, P., et al., "Long-Term Histologic Improvement And Loss Of Detectable Intrahepatic HCV RNA In Patients With Chronic Hepatitis C And Sustained Response To Interferon-alpha Therapy," <i>Ann. Inter. Med.</i> , November 15, 1997, pp. 875-881, vol. 127.
CM	MILLER, R.H., et al., "Hepatitis C Virus Shares Amino Acid Sequence Similarity With Pestiviruses And Flaviviruses As Well As Members Of Two Plant Virus Supergroups," <i>Proc. Natl. Acad. Sci. USA</i> , March 1990, pp. 2057-2061, vol. 87.
CN	MOLONEY, G.P., et al., "Synthesis and Serotonergic Activity of 2-oxadiazolyl-5-substituted-N,N-dimethyltryptamines: novel antagonists for the vascular 5-HT <sub>1B</sub> -like receptor" <i>J. Chem. Soc. Perkin</i> , 1999, pp. 2725-2733, vol. 19.
CO	MYLARI, B.L., et al., "Potent, orally active aldose reductase inhibitors related to zopolrestat: surrogates for benzothiazole side chain," <i>J. Med. Chem.</i> , 1992, pp. 457-465, vol. 35, issue 3.
CP	PALAZZO, G., et al., "1,2,4-Oxadiazoles--IV. Synthesis and Pharmacological Properties of a Series of Substituted Aminoalkyl-1,2,4-oxadiazoles," <i>J. Med. Pharm. Chem.</i> , 1961, pp. 351-367, vol. 4, issue 2.
CQ	POCH, O., et al., "Identification Of Four Conserved Motifs Among The RNA-Dependent Polymerase Encoding Elements" <i>The EMBO Journal</i> , 1989, pp. 3867-3874, vol 8, no. 12.
CR	POWELL, M.T., et al, "Optically active C <sup>3</sup> -symmetric triarylphosphines in asymmetric allylations," <i>Tetrahedron</i> , 2001, pp. 5027-5038, vol. 57.
CS	PROX, A., et. al., "Rapid Structure Elucidation of Drug Metabolites by Use of Stable Isotopes," <i>Xenobiotica</i> , 1973, pp. 103-112, vol. 3 no. 2.
CT	REN, R., et al., "Total Synthesis Of The Ocular Age Pigment A2-E: A Convergent Pathway," <i>J. Am. Chem. Soc.</i> , 1997, pp. 3619-3620, vol. 119.
CU	RINK, H., "Solid-Phase Synthesis Of Protected Peptide Fragments Using A Trialkoxy-Diphenyl-Methylester Resin," <i>Tetrahedron Letters</i> , 1987, pp. 3787-3790, vol. 28, no. 33.
CV	SELASSIE, C., et al., "QSAR For The Cytotoxicity Of 2-Alkyl Or 2,6-Fislkyl, 4-X-Phenols: The Nature Of The Radical Reaction," <i>J. Chem. Soc. Perkin Trans 2</i> , 2002, pp. 1112-1117.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/718,337
Filing Date	November 19, 2003
First Named Inventor	Allen BORCHARDT
Art Unit	1625
Examiner Name	To Be Assigned
Attorney Docket Number	PC25603A

	CW	SHAN, D., et al., "Prodrug Strategies Based On Intramolecular Cyclization Reactions" <i>J. Pharm. Sci.</i> , 1997, pp. 765-767, vol. 86, no. 7.	
	CX	SHISHOO, C. J., et al., "Reaction of Nitriles Under Acidic Conditions. Part III. A Facile Synthesis of Thienopyrimidin-4(3H)-ones," <i>J. Heterocyclic Chem.</i> , 1984, pp. 375-380, vol. 21.	
	CY	SIMMONDS, et al., "Classification Of Hepatitis C Virus Into Six Major Genotypes And A Series Of Subtypes By Phylogenetic Analysis Of The NS-5 Region" <i>Journal of General Virology</i> , 1993, pp. 2391-2399, Vol. 74.	
	CZ	SMITH, A. et al., "Photochemical Reactions of 1-Cyclopentenyl And 1-Cyclohexenyl Ketones" <i>Journal of American Chem. Soc.</i> , 1973, pp. 1961-1968.	
	DA	SPRAUL, M., et al., "Liquid Chromatography Coupled with High-Field Proton NMR for Profiling Human Urine for Endogenous Compounds and Drug Metabolites", <i>J. Pharmaceutical &amp; Biomedical Analysis</i> , 1992, pp. 601-605, vol. 10, issue 8.	
	DB	SZMUSZKOWICZ, J., et al., "A Study Of The Inhibitory Effect Of Various Hydrazides On Monoamine Oxidase <i>in vitro</i> And <i>in vivo</i> ," <i>Journal Of Medicinal And Pharmaceutical Chemistry</i> , 1961, pp. 259-296, vol. 4, no. 2.	
	DC	TANAKA, T., et al., "Structure Of The 3' Terminus Of The Hepatitis C Virus Genome," <i>Journal of Virology</i> , May 1996, pp. 3307-3312, vol. 70, no. 5.	
	DD	TEE, et al., "Kinetics and Mechanism of Bromination of 2-Pyridone and Related Derivatives in Aqueous Solution", <i>J. Am. Chem. Soc.</i> , 1982, pp. 4142-4246.	
	DE	VARA PRASAD, J.V.N., et al., "Nonpeptidic HIV Protease Inhibitors: 6-Alkyl-5,6-Dihydropyran-2-Ones Possessing Achiral 3-(4-Amino/Carboxamido-2- <i>t</i> -Butyl, 5-Methylphenyl Thio) Moiety: Antiviral Activities and Pharmacokinetic Properties," <i>Bioorg. Med. Chem. Lett.</i> , (07-06-1999), pp. 1481-1486, vol. 9, issue 11.	
	DF	VARA PRASAD, et al., "Nonpeptidic HIV Protease Inhibitors Processing Excellent Antiviral Activities and Therapeutic Indices. PD 178390: A Lead HIV Protease Inhibitor", <i>Bioorganic Medicinal Chemistry Letters</i> , 1999, pp. 2775-2800.	
	DG	WANG, et al., "Recent Advances In Prevention And Treatment Of Hepatitis C Virus Infections," <i>Progress in Drug Research</i> , 2000, pp. 1-32, vol. 55.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/718,337
Filing Date	November 19, 2003
First Named Inventor	Allen BORCHARDT
Art Unit	1625
Examiner Name	To Be Assigned
Attorney Docket Number	PC25603A

DH	WEINER, A.J., et al., "Evidence for Immune Selection of Hepatitis C Virus (HCV) Putative Envelope Glycoprotein Variants: Potential Role in Chronic HCV Infections", <i>Proc. Natl. Acad. Sci. USA</i> , 1992, pp. 3468-3472, vol. 89.
DI	WEINER, A.J., et al., "Variable And Hypervariable Domains Are Found In The Regions Of HCV Corresponding To The Flavivirus Envelope And NS1 Proteins And The Pestivirus Envelope Glycoproteins," <i>Virology</i> , 1991, pp. 842-848, vol. 180.
DJ	WYATT, C.A., et al., "Immunity In Chimpanzees Chronically Infected With Hepatitis C Virus: Role Of Minor Quasispecies In Reinfection" <i>Journal Of Virology</i> , March 1998, pp. 1725-1730, vol. 72, no. 3.
DK	YAMASHITA, T., et al., RNA-Dependant RNA Polymerase Activity of the Souable Recombinant Hepatitis C virus NS5B Protein Truncated at the C-Terminal Region, <i>J. Biol. Chem.</i> , 1998, pp. 15479-15486, vol. 273 (25).
DL	ZEUZEM, et al., "Hepatitis C Virus Dynamics In Vivo: Effect Of Ribavirin And Interferon Alfa On Viral Turnover" <i>Hepatology</i> , 1998, pp. 245-252.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.